Safety of total elbow arthroplasty in patients with rheumatoid arthritis and prior hip or knee periprosthetic joint infection

The volumes of upper and lower extremity arthroplasty are increasing. Periprosthetic joint infection (PJI) after TEA remains a substantial cause of morbidity, with certain studies reporting primary total elbow arthroplasties (TEA) PJI rates over 10%. The odds ratio for hip and knee PJI after previous hip or knee PJI is 3 times, and it rises to 15 times for patients on chronic suppressive antibiotics. The risk of PJI for primary TEA in patients with a history of lower extremity PJI is unknown. The purpose of this study, therefore, was to compare the incidence of PJI after primary TEA in patients with a history of lower extremity PJI in a case-control study. Our institutional joint registry database was queried to identify all patients who underwent primary TEA and had previously undergone treatment for lower extremity PJI between 1974 and 2021. Twelve elbows (10 patients) with a mean follow-up of 8.2 years were identified. There were 9 female elbows (75%) and 3 male elbows (25%) with a mean age of 63 years (range,44-78 years), and all patients had a diagnosis of rheumatoid arthritis. This cohort was 1:7 matched (age, sex, side, indication, and surgical year) to 84 elbows (83 patients) with no history of lower extremity PJI. There were no statistically significant differences between the cohorts with regard to body mass index or operative time. Survivorship analysis free of TEA PJI with death as a competing risk was calculated. None of the 12 TEA included in the study group developed PJI. The cumulative incidence of PJI in the matched cohort at 10 years was 6.4% (5 elbows). There was 1 superficial infection in the study group (9.1%) and 5 (5.8%) in the matched cohort. In the study group, 2 elbows underwent revision and 4 underwent reoperation. Eight elbows in the matched cohort underwent revision and 23 underwent reoperation. The study cohort was associated with higher risk of revision and reoperation for any cause, but these differences did not reach statistical significance. In this relatively small case control study, there was no incidence of PJI in patients who underwent primary TEA for rheumatoid arthritis and had previously undergone treatment for lower extremity PJI. The cumulative incidence of PJI in the matched cohort at 10 years was 6.4%. Although underpowered to make firm conclusions, it does draw from a very large population of patients and did not reveal an association between infection after TEA and a prior history of lower extremity PJI.